<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>antibody-drug conjugates &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/antibody-drug-conjugates/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 10 Nov 2025 15:19:21 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>antibody-drug conjugates &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Global Policymakers Confront Challenges in Financing New Treatments for Advanced Breast Cancer</title>
		<link>https://bioengineer.org/global-policymakers-confront-challenges-in-financing-new-treatments-for-advanced-breast-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 10 Nov 2025 15:18:56 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[antibody-drug conjugates]]></category>
		<category><![CDATA[Based on the content]]></category>
		<category><![CDATA[Cancer Drug Financing Challenges]]></category>
		<category><![CDATA[drug approval frameworks]]></category>
		<category><![CDATA[global health disparities]]></category>
		<category><![CDATA[Global Health Equity]]></category>
		<category><![CDATA[here are 5 relevant and specific tags: **cancer treatment financing challenges]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: **Advanced Breast Cancer Treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/global-policymakers-confront-challenges-in-financing-new-treatments-for-advanced-breast-cancer/</guid>

					<description><![CDATA[In recent advances presented at the Advanced Breast Cancer Eighth International Consensus Conference (ABC8) held in Lisbon, Portugal, experts have highlighted a growing paradox in the treatment landscape for advanced breast cancer (ABC): an unprecedented expansion in therapeutic options juxtaposed against prohibitive costs and unequal access. Professor Fatima Cardoso, President of the Advanced Breast Cancer [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">294110</post-id>	</item>
		<item>
		<title>TROP2: A Target for Cisplatin-Resistant Germ Cell Tumors</title>
		<link>https://bioengineer.org/trop2-a-target-for-cisplatin-resistant-germ-cell-tumors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 08 Oct 2025 08:31:38 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[antibody-drug conjugates]]></category>
		<category><![CDATA[apoptosis evasion mechanisms]]></category>
		<category><![CDATA[biomarker-driven oncology]]></category>
		<category><![CDATA[cancer research]]></category>
		<category><![CDATA[Chemoresistance mechanisms]]></category>
		<category><![CDATA[cisplatin-resistant germ cell tumors]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<category><![CDATA[TROP2]]></category>
		<category><![CDATA[TROP2-targeted therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/trop2-a-target-for-cisplatin-resistant-germ-cell-tumors/</guid>

					<description><![CDATA[Recent studies have highlighted the complexities and challenges in treating germ cell tumors, particularly those that exhibit resistance to standard chemotherapeutic agents like cisplatin. A landmark investigation has centered on the expression and therapeutic potential of TROP2, a protein that has garnered attention due to its prospective role in tumor biology and treatment response. Researchers [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">277434</post-id>	</item>
	</channel>
</rss>
